Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever
Tarih
2018Yazar
Korkmaz, Merve
Seyahi, Nurhan
Trabulus, Sinan
Kaya, Eda
Üst veri
Tüm öğe kaydını gösterÖzet
Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti-interleukin-1 drugs emerge as a therapeutic option for colchicine-resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.
Koleksiyonlar
- Makale [92796]